Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome&ndash;positive acute lymphoblastic leukemia

doi:10.7499/j.issn.1008-8830.2015.06.021

PDF(1174 KB)

Chinese Journal of Contemporary Pediatrics ›› 2015, Vol. 17 ›› Issue (6) : 634-637. DOI: 10.7499/j.issn.1008-8830.2015.06.021

CLINICAL EXPERIENCE

Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome–positive acute lymphoblastic leukemia

GUO Ye, LIU Tian-Feng, YANG Wen-Yu, et al.

Author information +

History +

Abstract

No abstract available

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GUO Ye, LIU Tian-Feng, YANG Wen-Yu, et al.. Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome–positive acute lymphoblastic leukemia[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(6): 634-637 https://doi.org/10.7499/j.issn.1008-8830.2015.06.021

References

[1] Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia[J]. N Engl J Med, 2006, 354(2):166-178.
[2] Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000, 342(14):998- 1006.
[3] Schultz KR, Bowman WP, Aledo A, et al. Improved early eventfree survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia:a children's oncology group study[J]. J Clin Oncol, 2009, 27(31):5175-5181.
[4] Schultz KR, Bowman WP, Aledo A, et al. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia (ALL) with longer term follow up:Updated Results of Children's Oncology Group (COG)AALL0031[J]. Pediatr Blood Cancer, 2010, 54:788.
[5] Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia:Children's Oncology Group Study AALL0031[J]. Leukemia, 2014, 28(7):1467-1471.
[6] 中华医学会儿科学分会血液学组. 2014 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9):641-644.
[7] 杨文钰, 王慧君, 陈玉梅, 等. 脑脊液流式细胞学检测技术在急性淋巴细胞白血病儿童并发中枢神经系统白血病中的诊断价值[J]. 中国实验血液学杂志, 2012, 20(1):38-42.
[8] Common Terminology Criteria for Adverse Events (CTCAE)[S].Version 4.0. Department of Health and Human Services, National Institutes of Health National Cancer Institute, US. 2009.
[9] Ramirez P, DiPersio JF. Therapy options in imatinib failures[J]. Oncologist, 2008,13(4):424-434.
[10] Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2008, 49(1):19-26.
[11] Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia:an update of concepts and management recommendations of European Leukemia[J]. Net. J Clin Oncol, 2009, 27(35):6041- 6051.
[12] Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia[J]. Blood, 2008, 112(4):1005-1012.
[13] Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib:a report from the children's oncology group phase I consortium[J]. J Clin Oncol, 2011, 29(7):839-844.
[14] Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia[J]. Hematol Am Soc Hematol Educ Program, 2011, 2011:361-365.
[15] Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib:a report from the children's oncology group phase I consortium[J]. J Clin Oncol, 2011, 29(7):839-844.
[16] Jeha S, Coustan-Smith E, Pei D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Cancer, 2014, 120(10):1514-1519.
[17] Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation:the potential of real-time quantitative reversetranscription polymerase chain reaction[J]. Br J Haematol, 2003, 120(1):145-153.
[18] Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy[J]. Blood, 2013, 122(7):1214- 1221.